List of Excipients in Branded Drug CHOLESTYRAMINE FOR ORAL SUSPENSION

« Back to Dashboard

Generic Drugs Containing CHOLESTYRAMINE FOR ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
Chartwell RX LLC	cholestyramine for oral suspension	62135-008	AMMONIUM GLYCYRRHIZATE
Chartwell RX LLC	cholestyramine for oral suspension	62135-008	ANHYDROUS CITRIC ACID
Chartwell RX LLC	cholestyramine for oral suspension	62135-008	D&C RED NO. 30
Chartwell RX LLC	cholestyramine for oral suspension	62135-008	FRUCTOSE
Chartwell RX LLC	cholestyramine for oral suspension	62135-008	PECTIN

What are the Most Frequently-Used Excipients in CHOLESTYRAMINE FOR ORAL SUSPENSION?

# Of NDCs	Excipient
1	AMMONIUM GLYCYRRHIZATE
1	ANHYDROUS CITRIC ACID
1	D&C RED NO. 30
1	FRUCTOSE
1	PECTIN

Cholestyramine for Oral Suspension Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 9, 2026

Cholestyramine for oral suspension is an established prescription bile acid sequestrant with a low-risk active pharmaceutical ingredient and limited apparent patent protection. Commercial differentiation depends on excipient engineering, palatability, dose convenience, packaging, and supply reliability rather than new chemical entity exclusivity. The strongest opportunities are sugar-free formulations, improved dispersion, single-dose packaging, better flavor systems, and products designed for pediatric, geriatric, and chronic-use patients.

What is cholestyramine for oral suspension?

Cholestyramine is a nonabsorbed anion-exchange resin that binds bile acids in the intestinal tract. FDA-approved uses include reduction of elevated low-density lipoprotein cholesterol and relief of pruritus associated with partial biliary obstruction [1,2].

The product is supplied as a powder that must be mixed with water or another compatible liquid before administration. Typical labeled dosing is 4 grams once or twice daily, with maintenance doses ranging from 4 to 8 grams daily and a labeled maximum of 24 grams daily, depending on the indication and patient response [1,2].

Because the resin is not systemically absorbed, the principal formulation risks are:

• Poor wetting and clumping
• Incomplete dispersion
• Gritty or chalky mouthfeel
• Unacceptable flavor
• Dose loss on the container or mixing vessel
• Drug binding and administration-separation errors
• Excipient-related issues such as sugar exposure or phenylalanine exposure

The active ingredient is generally described as cholestyramine resin USP. Product performance is determined heavily by particle size, moisture, ion-exchange capacity, bulk density, and excipient selection.

What excipients are used in cholestyramine oral suspension products?

Commercial products use excipients to improve taste, flow, dispersion, stability, and consumer acceptability. Exact compositions vary by manufacturer and product version.

Excipient function	Common strategy	Commercial purpose
Sweetening	Sucrose, aspartame, or other high-intensity sweeteners	Reduces resin bitterness and improves adherence
Acidulant	Citric acid	Provides flavor balance and supports a fruit profile
Flavoring	Orange, citrus, fruit, or mixed flavors	Masks resin taste and odor
Bulking agent	Maltodextrin and related carriers	Improves powder handling and flavor distribution
Suspending or dispersing aid	Xanthan gum or similar polymer	Supports wetting and dispersion
Flow and processing aid	Colloidal silica or other flow-control materials	Reduces segregation and improves filling
Colorant	Product-specific permitted colorants	Supports flavor recognition and brand differentiation
Texture modifier	Hydrocolloids or soluble carbohydrate systems	Reduces grittiness and improves suspension behavior

Prevalite labeling identifies inactive ingredients that may include aspartame, citric acid, flavoring, maltodextrin, and xanthan gum, depending on the product presentation [2]. Questran and other branded or generic versions have used different flavor, sweetener, and carrier systems. Product-specific DailyMed labeling should control any final composition assessment [3].

The formulation target is not a fully dissolved solution. Cholestyramine remains dispersed as a resin system. An excipient program therefore should optimize rapid wetting and uniform suspension rather than pursue conventional solution clarity.

What excipient attributes matter most commercially?

Dispersibility and reconstitution speed

Patients commonly prepare the product in a glass or cup immediately before dosing. A powder that floats, forms a surface film, or settles rapidly creates underdosing risk and reduces adherence.

A competitive formulation should target:

• Rapid wetting without persistent floating
• Low clump formation
• Uniform dispersion after ordinary stirring
• Acceptable suspension time during administration
• Low residue on the mixing container
• Reproducible performance across water, juice, and other label-permitted vehicles

Xanthan gum or a comparable hydrocolloid can improve suspension behavior, but excessive viscosity can make the product difficult to drink and can increase container residue. The formulation must balance suspension stability against pourability and mouthfeel.

Palatability and chronic-use adherence

Cholestyramine is used chronically for lipid management and may be used for extended periods in cholestatic pruritus. Flavor failure is therefore a commercial problem, not a cosmetic issue.

Useful development approaches include:

• Citrus or fruit flavors with acidulant support
• Sweetener systems that reduce lingering aftertaste
• Reduced resin odor
• Lower grit perception
• Flavor systems that remain effective after storage
• Separate pediatric and adult flavor profiles

A sugar-free, aspartame-free product could address patients with diabetes, phenylketonuria, or preferences against sucrose. An aspartame-containing product may require phenylalanine labeling under FDA requirements [4].

Powder flow and dose uniformity

The product is administered by mass, often using a scoop or packet. Density variation can create filling and dose-uniformity problems. Excipient selection should support:

• Consistent bulk density
• Low segregation during blending
• Stable fill weight
• Low dust generation
• Robust packet or bottle filling
• Reliable scoop delivery after repeated opening

Maltodextrin and other carriers can improve powder handling but may alter density, hygroscopicity, and flavor release. Hydrocolloids can improve suspension but may worsen flow if added at excessive levels.

What formulations are protected by patents?

The core cholestyramine molecule and conventional oral suspension concept are old. The main U.S. commercial opportunity is therefore unlikely to depend on active-ingredient patent exclusivity.

Potentially protectable technical features include:

• Specific particle-size distributions
• Defined ion-exchange capacity or resin specifications
• Low-dust granules
• Taste-masked particles
• Improved wetting systems
• Specific hydrocolloid combinations
• Sugar-free or phenylalanine-free compositions
• Unit-dose sachets with controlled moisture exposure
• Ready-to-drink or liquid-dispersible presentations
• Manufacturing processes that reduce segregation or improve content uniformity

A formulation patent would need to claim a measurable technical distinction, such as improved dispersion time, reduced sedimentation, improved palatability, or enhanced stability. Broad claims covering cholestyramine powder plus ordinary flavor, sweetener, or acidulant excipients would face meaningful obviousness risk because these excipient categories are conventional.

No current broad U.S. composition-of-matter barrier is expected to prevent generic development. The commercial value of any formulation patent would depend on whether the claim covers a clinically or commercially meaningful product attribute and whether the product is listed in the FDA Orange Book.

What is the Orange Book status of cholestyramine for oral suspension?

Cholestyramine products are prescription drugs, and FDA-approved products may be listed in the Orange Book by reference product, dosage form, route, and therapeutic equivalence status [5].

The central regulatory points are:

Issue	Assessment
Regulatory status	Prescription drug
Dosage form	Powder for oral suspension
Active ingredient	Cholestyramine resin
Absorption	Not systemically absorbed to a meaningful extent
New chemical entity exclusivity	Not relevant to this established active ingredient
Broad active-ingredient patent barrier	Not expected
Generic pathway	Generally an ANDA strategy for therapeutically equivalent powder products
505(b)(2) opportunity	Possible for materially different delivery, formulation, or dosage presentation
Biosimilar pathway	Not applicable
Paragraph IV risk	Product-specific and dependent on any currently listed Orange Book patents

An applicant pursuing an ANDA must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA’s product-specific requirements. Because cholestyramine is nonabsorbed, conventional plasma-concentration bioequivalence may not be sufficient or applicable in the same manner as for systemically absorbed drugs. FDA may rely on product-specific in vitro, physicochemical, pharmacodynamic, or other performance requirements.

When does cholestyramine lose exclusivity?

Cholestyramine lost practical new-drug exclusivity many years ago. Questran was approved in the 1970s, and generic cholestyramine products have been marketed for decades [1,5].

There is no meaningful current NCE exclusivity period for the established active ingredient. Any remaining exclusivity analysis must focus on:

• Product-specific patents listed in the Orange Book
• Formulation or delivery patents
• Manufacturing process rights
• Trade secrets
• Brand recognition
• Contracting and distribution arrangements
• Regulatory barriers associated with demonstrating equivalence

The commercial exclusivity period for a newly developed cholestyramine formulation would depend on its regulatory pathway and whether it contains a patentable improvement. A new formulation approved through a 505(b)(2) application could receive product-specific regulatory exclusivity in limited circumstances, but the commercial scope would not automatically block existing generic powder products.

Which companies are challenging cholestyramine patents?

No widely reported current Paragraph IV campaign is associated with a broad, active cholestyramine patent estate. Multiple manufacturers have historically supplied generic cholestyramine powder products, indicating that the core product is commercially open to competition.

Paragraph IV litigation would become relevant only if a sponsor listed a formulation or delivery patent in the Orange Book and a generic applicant certified that the patent was invalid, unenforceable, or would not be infringed. The likely dispute areas would be:

• Whether the generic has the same formulation characteristics
• Whether a specific excipient combination is claimed
• Whether a process claim can reach the commercial product
• Whether the listed patent properly qualifies for Orange Book listing
• Whether the proposed product is carved out from a patented method of use

What method-of-use patents affect cholestyramine?

The principal indications are hypercholesterolemia and pruritus associated with partial biliary obstruction. These uses are old and are unlikely to support a strong current exclusivity position.

A later method-of-use patent could theoretically cover:

• A specific dosing regimen
• Use in a narrowly defined patient population
• Treatment of a distinct bile-acid-mediated condition
• A combination regimen with another drug
• A formulation-specific administration protocol

The practical value of such a patent would depend on whether the indication is carved out from the generic label and whether prescribing behavior is sufficiently concentrated in the patented use. For an old, low-cost medicine, method-of-use enforcement would likely be more difficult than product differentiation through packaging and patient usability.

What generic launch risks exist?

Generic entry risk is high for conventional cholestyramine powder. The active ingredient is old, multiple products have been marketed, and physician familiarity is established.

The principal launch risks are operational rather than patent-based:

1. Failure to match the reference product’s particle or resin attributes.
2. Inadequate dispersion after mixing.
3. Poor taste leading to low refill persistence.
4. Packet or bottle moisture ingress.
5. Inconsistent fill weight or scoop delivery.
6. Manufacturing constraints for low-density, dusty resin powder.
7. Limited access to qualified cholestyramine resin suppliers.
8. FDA questions regarding equivalence for a nonabsorbed product.
9. Medication-interaction concerns that affect labeling and patient use.

Generic substitution may be influenced by flavor, package size, pharmacy stocking, and payer contracting. A technically equivalent but poorly tolerated product can lose share to a branded or better-presented generic competitor.

How strong is the patent estate for cholestyramine oral suspension?

The patent estate is weak for the conventional product and potentially moderate for a differentiated formulation.

Asset category	Likely strength
Cholestyramine active ingredient	Very weak or expired
Conventional powder for suspension	Weak
Standard flavor and sweetener system	Weak
Specific low-grit formulation	Moderate if supported by comparative data
Unit-dose moisture-protective package	Moderate, often design-around prone
Novel liquid or ready-to-drink system	Potentially moderate to strong
Manufacturing process	Moderate if process-specific and difficult to reproduce
Method of use	Weak for legacy indications; variable for new indications
Trade secret manufacturing know-how	Potentially important
Brand and distribution	More commercially relevant than core patents

A strong filing would require comparative data against marketed products. Useful endpoints include dispersion time, sedimentation rate, residue, particle-size distribution, moisture uptake, flavor scores, fill-weight variation, and stability after package opening.

What licensing deals and manufacturing barriers matter?

Publicly visible licensing activity is limited for legacy cholestyramine products. The most relevant commercial arrangements are likely to involve:

• Supply of pharmaceutical-grade cholestyramine resin
• Contract manufacturing of low-density powders
• Flavor and masking technology
• Sachet and moisture-barrier packaging
• Distribution rights for branded generic products
• Product acquisition or in-licensing of approved ANDAs

Manufacturing is a meaningful barrier because cholestyramine powders can be dusty, difficult to blend, and sensitive to density variation. A developer that controls resin sourcing, particle engineering, flavor incorporation, and high-throughput filling can create an advantage that is difficult to reproduce quickly, even without strong patent protection.

What commercial opportunities exist for excipient innovation?

The highest-value opportunities are patient-use improvements rather than changes to pharmacology.

Sugar-free and phenylalanine-free products

A formulation that avoids sucrose and aspartame could target patients with diabetes, phenylketonuria, or strong preferences against artificial sweeteners. The product would need an effective alternative sweetener and flavor system without increasing bitterness or aftertaste.

Unit-dose sachets

Single-dose packaging can improve portability, reduce dosing errors, and support pharmacy dispensing. Moisture-barrier films are important because powder flow and dispersion can change with humidity exposure.

Improved pediatric formulation

Children may have difficulty consuming a large-volume, gritty suspension. A product with improved taste, smaller dose packets, and validated compatibility with commonly used pediatric vehicles could compete in a specialized segment. Any pediatric positioning would require appropriate regulatory support and careful control of drug-binding interactions.

Ready-to-drink or concentrated presentation

A liquid or concentrated product could reduce preparation burden. The technical challenges include maintaining resin suspension, preventing settling, controlling viscosity, and achieving adequate shelf stability. A ready-to-drink product would likely require a distinct regulatory and patent strategy.

Premium adherence product

A better-tasting, low-residue product could support premium pricing despite generic competition. The commercial case would require evidence of lower discontinuation, improved refill persistence, or reduced administration errors.

How does cholestyramine compare with competing bile acid sequestrants?

Product	Formulation	Key commercial distinction
Cholestyramine	Powder for oral suspension	Established, low-cost, but poor palatability and preparation burden
Colestipol	Granules or tablets	Alternative bile acid sequestrant with different dosage and administration characteristics
Colesevelam	Tablets or oral suspension	Generally easier administration but often higher cost and different regulatory and patent history

Cholestyramine’s principal competitive weakness is usability. Its principal strength is long market experience, low cost, and broad physician familiarity. Excipient innovation can narrow the usability gap without requiring a new active ingredient.

What revenue exposure and launch scenarios should investors consider?

Public product-level revenue disclosure is limited because cholestyramine products are often sold through generic, private-label, or diversified pharmaceutical portfolios. Revenue exposure is therefore more dependent on market share, payer access, manufacturing cost, and supply continuity than on patent-protected pricing.

Three launch scenarios are commercially relevant:

Scenario	Product profile	Expected market position
Commodity generic	Conventional powder, standard flavor, bottle or packet	Low price, high substitution pressure
Differentiated generic	Better taste, dispersion, packaging, or sugar-free profile	Potential premium and improved retention
Novel formulation	Ready-to-drink, pediatric, or specialized delivery system	Higher development cost and potential regulatory exclusivity

The most defensible strategy is a differentiated generic with measurable usability advantages and a focused packaging platform. A wholly novel dosage form could create stronger intellectual property but would face higher development, manufacturing, and regulatory costs.

Key Takeaways

• Cholestyramine for oral suspension is an old, established prescription product with no meaningful NCE exclusivity.
• The core active ingredient and conventional powder format offer limited patent protection.
• Excipient selection determines palatability, dispersion, flow, dose uniformity, and chronic-use adherence.
• The strongest formulation opportunities are sugar-free products, improved taste, low-residue dispersion, unit-dose packaging, and pediatric-friendly presentations.
• Biosimilar risk is not applicable because cholestyramine is a nonbiologic small-molecule resin product.
• Paragraph IV risk is product-specific and likely limited unless a sponsor lists a new formulation or delivery patent.
• Manufacturing know-how and reliable resin sourcing may be more valuable than broad composition patents.
• A differentiated generic has a stronger commercial case than a commodity powder if the usability advantage is measurable.
• Ready-to-drink and specialized pediatric products offer greater differentiation but carry higher regulatory and technical risk.

FAQs About Cholestyramine Oral Suspension Patents and Excipient Development

Can cholestyramine oral suspension be developed as an ANDA product?

Yes. A conventional product that matches the reference product in active ingredient, dosage form, route, strength, and relevant quality attributes may be suitable for an ANDA, subject to FDA’s product-specific requirements.

Is cholestyramine a biologic that could face biosimilar competition?

No. Cholestyramine is a nonabsorbed anion-exchange resin and is regulated as a drug product, not as a biologic. Biosimilar law does not apply.

What is the most valuable excipient improvement for cholestyramine?

Improved palatability combined with rapid dispersion is likely the highest-value improvement because poor taste, grittiness, and preparation inconvenience directly affect chronic adherence.

Can a cholestyramine formulation receive new patent protection?

Yes, if the formulation contains a non-obvious, technically supported improvement. Claims based only on conventional flavoring, sweetening, or acidification would likely face a weaker patent position than claims tied to demonstrated performance gains.

Does cholestyramine bind other medicines?

Yes. Cholestyramine can reduce absorption of concomitant oral medicines. Product labeling generally instructs patients to take other drugs at least one hour before or four to six hours after cholestyramine [1,2].

References

1. U.S. Food and Drug Administration. (2023). Questran cholestyramine powder, for suspension prescribing information.
2. U.S. Food and Drug Administration. (2023). Prevalite cholestyramine powder, for suspension prescribing information.
3. National Library of Medicine. (2024). DailyMed: Cholestyramine powder for suspension product labeling.
4. U.S. Food and Drug Administration. (2023). Aspartame and other sweeteners in FDA-regulated products.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.